Geode Capital Management LLC Has $6.01 Million Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Geode Capital Management LLC cut its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 2.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,114,628 shares of the biotechnology company’s stock after selling 23,415 shares during the quarter. Geode Capital Management LLC’s holdings in Aldeyra Therapeutics were worth $6,009,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ALDX. Perceptive Advisors LLC increased its stake in shares of Aldeyra Therapeutics by 7.9% in the second quarter. Perceptive Advisors LLC now owns 9,275,851 shares of the biotechnology company’s stock valued at $30,703,000 after buying an additional 682,265 shares during the period. State Street Corp grew its holdings in Aldeyra Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock worth $5,249,000 after acquiring an additional 16,188 shares during the last quarter. Federated Hermes Inc. acquired a new position in Aldeyra Therapeutics in the 2nd quarter valued at approximately $1,758,000. Jacobs Levy Equity Management Inc. raised its stake in shares of Aldeyra Therapeutics by 163.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after acquiring an additional 295,864 shares during the last quarter. Finally, PFG Investments LLC acquired a new position in shares of Aldeyra Therapeutics during the second quarter worth $1,312,000. 59.71% of the stock is owned by institutional investors and hedge funds.

Aldeyra Therapeutics Stock Performance

Shares of Aldeyra Therapeutics stock opened at $5.45 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. Aldeyra Therapeutics, Inc has a twelve month low of $2.71 and a twelve month high of $6.55. The company’s fifty day moving average is $5.02 and its 200 day moving average is $4.85.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, meeting analysts’ consensus estimates of ($0.25). On average, sell-side analysts predict that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.